In his first term, Trump made a lot of noise about lowering drug prices but accomplished little of consequence. The noise continues, but it is now accompanied by new ill-conceived initiatives, ...

The pharmaceutical industry’s lobbying muscle scored a high-stakes victory on Monday when the Senate parliamentarian reversed a previous decision and ruled that the Optimizing Research Progress Hope ...

The bill would cut $1.1 trillion in health-care spending and result in 11.8 million people losing health coverage over the ...

The Senate passed its version of the GOP megabill on Tuesday, and big players across the health care industry have been quick ...

STAFFING UP: Liberal legal advocacy group Democracy Forward has announced a slate of additions to its legal team. The group has added Joshua Salzman, Yenisey Rodríguez and Nathaniel Zelinsky as senior ...

The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

Legislation passed by the Senate on Tuesday could affect how people sign up for Medicaid and the insurance marketplaces, and ...

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

The popular program helps seniors make informed choices when deciding which Medicare plans are right for them.

Amanda Chu of POLITICO reveals how lawmakers are betting millions on pharma stocks even as Trump threatens tariffs and demands steep drug price cuts. Watch!

In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy benefit manager reform, and implications for manufacturers and patients.

The Senate version of the legislation makes even steeper cuts to Medicaid than the $800 billion slashed in the House-passed version of the bill.